Model:656599020914
Current Reviews:0
Price:$7.00

Gliburyde (Lawazin) 5mg 100 Tabs, Glibenclamide

THERAPEUTIC INDICATIONS: Diabetes mellitus non-insulin dependent (Type II), when blood glucose levels can not be adequately controlled through diet, exercise and weight reduction.

When the efficacy of glibenclamide decreases can be administered together with insulin.

Glibenclamide, which acts on the pancreatic beta cells can also be combined with other oral antidiabetic non-betacitotrópico (for jrmplo: biguanides, thiazolidinediones, alpha-glucosidase inhibitors).

CONTRAINDICATIONS: GLIBENCLAMIDE ® should not be administered:

- Patients with insulin-dependent diabetes mellitus (Type I).

- Diabetic ketoacidosis.

- Pre-coma or diabetic coma.

- Patients with severe renal impairment (creatinine clearance approximately 30 ml / min).

- Patients with severe hepatic impairment.

- Patients with hypersensitivity to glyburide

- Patients with hypersensitivity to any ingredient in GLIBENCLAMIDE®.

- Patients who are pregnant.

- Patients who are breastfeeding.

- Patients treated with bosentan.

CAUTIONS:

General: Alertness and reactions hypoglycemic or hyperglycemic episodes may worsen, especially when beginning or alternating treatment, or when taken regularly GLIBENCLAMIDE ®. This may, for example, affect the ability to drive, cross the road safely or operate machinery.

To achieve the goal of treatment with GLIBENCLAMIDE ®-optimal control of blood glucose-adherence to proper diet, regular exercise and adequate and, if necessary, weight reduction as necessary as regular intake of GLIBENCLAMIDE ®.

The clinical signs of hyperglycemia increase, urinary frequency, thirst, dry mouth and dry skin.

At the start of treatment, you should inform the patient about the effects and risks of Euglucon ® and about their interaction with dietary measures and physical exercise should also highlight the importance of good cooperation.

As with any glucose-lowering therapy, the patient and physician must be aware of the risk of hypoglycemia.

The factors contributing to hypoglycemia include:

- Failure or inability of the patient to cooperate (most commonly in elderly patients).

- Malnutrition, irregular meal times or skipped meals.

- Changes in diet or unaccustomed physical exertion.

- Consumption of alcohol, especially in combination with skipped meals.

- Renal dysfunction.

- Severe liver dysfunction.

DOSAGE AND ADMINISTRATION:

Oral.

Adults: Start with 5 mg/24 hours. If a week is not achieved good control of diabetes, you can adjust the dose at 2.5 mg at weekly intervals. The maximum maintenance dose recommendedis 15 mg / day. For proper administration preferably taking a single dose in the morning before breakfast. If doses above 10 mg / day may be convenient to administer twice a day.

Change to other hypoglycemic GLIBENCLAMIDE: You should begin treatment within 24 hoursof the last shot of the previous product, starting with half a tablet (2.5 mg) and continue thedosing schedule described above. If a replacement is hypoglycemic chlorpropamide shouldwait 48 hours before starting the administration of glibenclamide, but best medical opinion.

Name of the medication: Lawazin
Comparative brand name medication: Glyburide
Active substance: glibenclamide
Presentation: Tablets
Concentration: 5 mg
Time release: No
Laboratory: Victory Enterprises
Box with 100 pills
Made in: Mexico